Annual Accounts Receivable
$126.10 K
-$1.95 M-93.93%
01 December 2023
Summary:
COSCIENS Biopharma annual accounts receivable is currently $126.10 thousand, with the most recent change of -$1.95 million (-93.93%) on 01 December 2023. During the last 3 years, it has fallen by -$1.46 million (-92.04%).CSCI Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$1.89 M
+$654.00 K+52.83%
01 September 2024
Summary:
COSCIENS Biopharma quarterly accounts receivable is currently $1.89 million, with the most recent change of +$654.00 thousand (+52.83%) on 01 September 2024. Over the past year, it has increased by +$1.17 million (+161.65%).CSCI Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -93.9% | +161.7% |
| 3 y3 years | -92.0% | -11.2% |
| 5 y5 years | -94.3% | +8.4% |
CSCI Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -95.5% | -33.3% |
COSCIENS Biopharma Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.89 M(+52.8%) |
| June 2024 | - | $1.24 M(-0.3%) |
| Mar 2024 | - | $1.24 M(+884.8%) |
| Dec 2023 | $126.10 K(-93.9%) | $126.10 K(-82.6%) |
| Sept 2023 | - | $723.10 K(-38.7%) |
| June 2023 | - | $1.18 M(-45.2%) |
| Mar 2023 | - | $2.15 M(+3.6%) |
| Dec 2022 | $2.08 M(+26.6%) | $2.08 M(-2.4%) |
| Sept 2022 | - | $2.13 M(-18.4%) |
| June 2022 | - | $2.61 M(-8.0%) |
| Mar 2022 | - | $2.84 M(+72.8%) |
| Dec 2021 | $1.64 M(+3.6%) | $1.64 M(-22.9%) |
| Sept 2021 | - | $2.13 M(+46.6%) |
| June 2021 | - | $1.45 M(-36.9%) |
| Mar 2021 | - | $2.30 M(+45.4%) |
| Dec 2020 | $1.58 M(-43.5%) | $1.58 M(+15.3%) |
| Sept 2020 | - | $1.37 M(-38.7%) |
| June 2020 | - | $2.24 M(-19.1%) |
| Mar 2020 | - | $2.77 M(-1.2%) |
| Dec 2019 | $2.80 M(+26.5%) | $2.80 M(+60.5%) |
| Sept 2019 | - | $1.75 M(+3.2%) |
| June 2019 | - | $1.69 M(-10.6%) |
| Mar 2019 | - | $1.89 M(-14.6%) |
| Dec 2018 | $2.21 M(+123.4%) | $2.21 M(+326.0%) |
| Sept 2018 | - | $519.70 K(-47.7%) |
| June 2018 | - | $993.30 K(+76.1%) |
| Mar 2018 | - | $564.00 K(-43.1%) |
| Dec 2017 | $991.20 K(+136.1%) | $991.20 K(-2.9%) |
| Sept 2017 | - | $1.02 M(-6.4%) |
| June 2017 | - | $1.09 M(+30.8%) |
| Mar 2017 | - | $833.80 K(+98.0%) |
| Dec 2016 | $419.80 K(+8.1%) | $421.10 K(-41.9%) |
| Sept 2016 | - | $724.20 K(-29.7%) |
| June 2016 | - | $1.03 M(+822.6%) |
| Mar 2016 | - | $111.60 K(-71.3%) |
| Dec 2015 | $388.40 K(+6.4%) | $388.40 K(-9.4%) |
| Sept 2015 | - | $428.80 K(-35.0%) |
| June 2015 | - | $659.90 K(+99.7%) |
| Mar 2015 | - | $330.40 K(-9.5%) |
| Dec 2014 | $364.90 K(+54.9%) | $364.90 K(-15.4%) |
| Sept 2014 | - | $431.20 K(-33.4%) |
| June 2014 | - | $647.90 K(+98.2%) |
| Mar 2014 | - | $326.90 K(+38.8%) |
| Dec 2013 | $235.60 K(-7.5%) | $235.60 K(-50.9%) |
| Sept 2013 | - | $479.80 K(+0.8%) |
| June 2013 | - | $475.90 K(-29.6%) |
| Mar 2013 | - | $675.90 K(+165.4%) |
| Dec 2012 | $254.70 K(-44.1%) | $254.70 K(-1.1%) |
| Sept 2012 | - | $257.60 K(-6.7%) |
| June 2012 | - | $276.20 K(-42.5%) |
| Mar 2012 | - | $480.10 K(+5.3%) |
| Dec 2011 | $455.90 K(-20.1%) | $455.90 K(+93.3%) |
| Sept 2011 | - | $235.80 K(-33.0%) |
| June 2011 | - | $351.90 K(-23.1%) |
| Mar 2011 | - | $457.40 K(-19.8%) |
| Dec 2010 | $570.30 K | $570.30 K(+14.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $499.60 K(+28.9%) |
| June 2010 | - | $387.50 K(+46.0%) |
| Mar 2010 | - | $265.40 K(+83.9%) |
| Dec 2009 | $143.40 K(-68.0%) | $144.30 K(-77.9%) |
| Sept 2009 | - | $652.50 K(+27.9%) |
| June 2009 | - | $510.10 K(+8.8%) |
| Mar 2009 | - | $468.80 K(+3.4%) |
| Dec 2008 | $447.70 K(-36.9%) | $453.20 K(+20.4%) |
| Sept 2008 | - | $376.30 K(-50.0%) |
| June 2008 | - | $752.30 K(-19.0%) |
| Mar 2008 | - | $929.10 K(+29.9%) |
| Dec 2007 | $709.50 K(+30.4%) | $715.10 K(+186.4%) |
| Sept 2007 | - | $249.70 K(-72.3%) |
| June 2007 | - | $899.90 K(+6.0%) |
| Mar 2007 | - | $849.30 K(+56.1%) |
| Dec 2006 | $543.90 K(-35.7%) | $544.10 K(+40.6%) |
| Sept 2006 | - | $387.10 K(-38.7%) |
| June 2006 | - | $631.50 K(-15.6%) |
| Mar 2006 | - | $748.20 K(-11.5%) |
| Dec 2005 | $845.30 K(+170.8%) | $845.80 K(+161.6%) |
| Sept 2005 | - | $323.30 K(-33.6%) |
| June 2005 | - | $487.10 K(+26.0%) |
| Mar 2005 | - | $386.60 K(+23.9%) |
| Dec 2004 | $312.20 K(-21.1%) | $312.10 K(+198.1%) |
| Sept 2004 | - | $104.70 K(-82.9%) |
| June 2004 | - | $612.40 K(+67.4%) |
| Mar 2004 | - | $365.80 K(-7.7%) |
| Dec 2003 | $395.90 K(+127.3%) | $396.50 K(+14.5%) |
| Sept 2003 | - | $346.40 K(+49.0%) |
| June 2003 | - | $232.50 K(+31.1%) |
| Mar 2003 | - | $177.40 K(+1.6%) |
| Dec 2002 | $174.20 K(+248.4%) | $174.60 K(-2.3%) |
| Sept 2002 | - | $178.80 K(-32.7%) |
| June 2002 | - | $265.50 K(+220.3%) |
| Mar 2002 | - | $82.90 K(+65.1%) |
| Dec 2001 | $50.00 K(+6.6%) | $50.20 K(-62.4%) |
| Sept 2001 | - | $133.50 K(-15.5%) |
| June 2001 | - | $158.00 K(+47.7%) |
| Mar 2001 | - | $107.00 K(+128.1%) |
| Dec 2000 | $46.90 K(-31.8%) | $46.90 K(-77.9%) |
| Sept 2000 | - | $211.80 K(+56.9%) |
| June 2000 | - | $135.00 K(-2.0%) |
| Mar 2000 | - | $137.70 K(+99.6%) |
| Dec 1999 | $68.80 K(+6.5%) | $69.00 K(+1.3%) |
| Sept 1999 | - | $68.10 K(+0.4%) |
| June 1999 | - | $67.80 K(-48.8%) |
| Mar 1999 | - | $132.50 K(+103.8%) |
| Dec 1998 | $64.60 K(-53.7%) | $65.00 K(-0.8%) |
| Sept 1998 | - | $65.50 K(-67.9%) |
| June 1998 | - | $204.20 K(+44.9%) |
| Mar 1998 | - | $140.90 K(+0.8%) |
| Dec 1997 | $139.50 K(-84.1%) | $139.80 K(-82.4%) |
| Sept 1997 | - | $796.30 K(-8.4%) |
| June 1997 | - | $869.20 K(-7.7%) |
| Mar 1997 | - | $942.10 K |
| Dec 1996 | $875.90 K | - |
FAQ
- What is COSCIENS Biopharma annual accounts receivable?
- What is the all time high annual accounts receivable for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual accounts receivable year-on-year change?
- What is COSCIENS Biopharma quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly accounts receivable year-on-year change?
What is COSCIENS Biopharma annual accounts receivable?
The current annual accounts receivable of CSCI is $126.10 K
What is the all time high annual accounts receivable for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual accounts receivable is $2.80 M
What is COSCIENS Biopharma annual accounts receivable year-on-year change?
Over the past year, CSCI annual accounts receivable has changed by -$1.95 M (-93.93%)
What is COSCIENS Biopharma quarterly accounts receivable?
The current quarterly accounts receivable of CSCI is $1.89 M
What is the all time high quarterly accounts receivable for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly accounts receivable is $2.84 M
What is COSCIENS Biopharma quarterly accounts receivable year-on-year change?
Over the past year, CSCI quarterly accounts receivable has changed by +$1.17 M (+161.65%)